MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1234-1237. doi: 10.15585/mmwr.mm6544e1.
Candida auris, an emerging fungus that can cause invasive infections, is associated with high mortality and is often resistant to multiple antifungal drugs. C. auris was first described in 2009 after being isolated from external ear canal discharge of a patient in Japan (1). Since then, reports of C. auris infections, including bloodstream infections, have been published from several countries, including Colombia, India, Israel, Kenya, Kuwait, Pakistan, South Africa, South Korea, Venezuela, and the United Kingdom (2-7). To determine whether C. auris is present in the United States and to prepare for the possibility of transmission, CDC issued a clinical alert in June 2016 informing clinicians, laboratorians, infection control practitioners, and public health authorities about C. auris and requesting that C. auris cases be reported to state and local health departments and CDC (8). This report describes the first seven U.S. cases of C. auris infection reported to CDC as of August 31, 2016. Data from these cases suggest that transmission of C. auris might have occurred in U.S. health care facilities and demonstrate the need for attention to infection control measures to control the spread of this pathogen.
耳念珠菌是一种新兴的真菌,可引起侵袭性感染,死亡率高,且通常对多种抗真菌药物具有耐药性。2009 年,首次从日本一名患者的外耳道分泌物中分离出耳念珠菌(1)。此后,包括血流感染在内的耳念珠菌感染病例报告陆续来自哥伦比亚、印度、以色列、肯尼亚、科威特、巴基斯坦、南非、韩国、委内瑞拉和英国等多个国家(2-7)。为确定美国是否存在耳念珠菌以及为可能发生的传播做好准备,美国疾病预防控制中心于 2016 年 6 月发布了临床警示,向临床医生、实验室人员、感染控制从业者和公共卫生部门通报了耳念珠菌的相关情况,并要求将耳念珠菌病例报告给州和地方卫生部门以及美国疾病预防控制中心(8)。本报告描述了截至 2016 年 8 月 31 日,美国疾病预防控制中心报告的首例 7 例耳念珠菌感染病例。这些病例的数据表明,耳念珠菌可能已在美国医疗机构中传播,这凸显了必须重视感染控制措施,以控制这种病原体的传播。